Key result
Immunoadsorption in β1-AAB-positive patients with end-stage dilated cardiomyopathy was associated with higher 5-year transplant/VAD-free survival compared to no immunoadsorption (69.4% vs 25.4%, P<0.05).
Why the study?
Does immunoadsorption improve cardiac function and HTx/VAD-free survival in β1-adrenoceptor autoantibody-positive transplant candidates with end-stage dilated cardiomyopathy?
Cohort
No
Does immunoadsorption improve cardiac function and HTx/VAD-free survival in β1-adrenoceptor autoantibody-positive transplant candidates with end-stage dilated cardiomyopathy?
Absolute Event Rate: 69.4% vs 25.4%
p-value: p=< 0.05
Immunoadsorption significantly improves long-term HTx/VAD-free survival and cardiac function in β1-adrenoceptor autoantibody-positive patients with end-stage dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
May support consideration in selected patients; leaves open need for RCTs to confirm benefit in end-stage DCM.
Dandel et al. (2012) conducted a cohort in End-stage dilated cardiomyopathy. Immunoadsorption vs. No immunoadsorption therapy was evaluated on 5-year HTx/VAD-free survival (p=< 0.05). Immunoadsorption in β1-AAB-positive patients with end-stage dilated cardiomyopathy was associated with higher 5-year transplant/VAD-free survival compared to no immunoadsorption (69.4% vs 25.4%, P<0.05).